Already a DIA Member? Sign in. Not a member? Join.
Sign in
Not a Member?
Antibody-Drug Conjugates: Simple Idea, Complicated Matter
Published Date: Oct 01, 2020Challenges with ADCs have led to novel ideas such as non-toxic payloads that could convert to an active drug with additional triggers
Author(s)
Dr. John Leighton
Director, Division of Hematology Oncology Toxicology, OOD, OND, CDER
FDA
Dr. Leighton received his PhD from the Department of Physiology and Biophysics at the University of Illinois, Urbana-Champaign. Dr. Leighton first came to FDA as a pharmacology and toxicology reviewer in the Center for Veterinary Medicine and moved to the Division of Oncology Drug Products (DODP) in CDER as a reviewing pharmacologist, later serving as a supervisory pharmacologist. Dr. Leighton is currently the Director for the Division of Hematology Oncology Toxicology in the Office of Oncologic Diseases. Dr. Leighton was the FDA topic lead for ICH S9 and the Q&A.